Explore
Validate
LearnPA5-28827
antibody from Invitrogen Antibodies
Targeting: CXCL13
ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [1]
- Immunohistochemistry [4]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-28827 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CXCL13 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Recommended positive controls: CXCL13-transfected 293T.
- Concentration
- 1.31 mg/mL
Submitted references Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K, Cao Y, Gu Y, Fang H, Fei Y, Wang J, Liu X, Lv K, He X, Lin C, Liu H, Li H, He H, Li R, Zhang H, Xu J
Oncoimmunology 2021 Apr 27;10(1):1915560
Oncoimmunology 2021 Apr 27;10(1):1915560
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of BCA1 using 30 µg of HepG2 lysate. Samples were loaded onto a 15% SDS-PAGE gel and probed with a BCA1 polyclonal antibody (Product # PA5-28827) at a dilution of 1:1000.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of CXCL13 was performed by separating 60 µg of non-transfected (–) and transfected (+) 293T whole cell extracts by 15% SDS-PAGE. Proteins were transferred to a membrane and probed with a CXCL13 Polyclonal Antibody (Product # PA5-28827) at a dilution of 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot using CXCL13 Polyclonal Antibody (Product # PA5-28827). Non-transfected (–) and transfected (+) 293T whole cell extracts (30 µg) were separated by 15% SDS-PAGE, and the membrane was blotted with CXCL13 Polyclonal Antibody (Product # PA5-28827) diluted at 1:10,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry-Immunofluorescence analysis of CXCL13 was performed in HepG2 cells fixed in 4% paraformaldehyde at RT for 15 min. Green: CXCL13 Polyclonal Antibody (Product # PA5-28827) diluted at 1:500. Blue: Hoechst 33342 staining. Scale bar = 10 µm.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (Paraffin) analysis of CXCL13 was performed in paraffin-embedded human esophageal carcinoma tissue using CXCL13 Polyclonal Antibody (Product # PA5-28827) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (Paraffin) analysis of CXCL13 was performed in paraffin-embedded human esophageal carcinoma tissue using CXCL13 Polyclonal Antibody (Product # PA5-28827) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- CXCL13 Polyclonal Antibody detects BCA1 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded human esophageal carcinoma. BCA1 stained by CXCL13 Polyclonal Antibody (Product # PA5-28827) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- CXCL13 Polyclonal Antibody detects BCA1 protein at cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded human esophageal carcinoma. BCA1 stained by CXCL13 Polyclonal Antibody (Product # PA5-28827) diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1. Intratumoral CXCL13 + CD8 + T cells predict poor prognosis in gastric cancer. (a) Immunohistochemical double-staining of CD8 (brown) and CXCL13 (blue) in gastric cancer tissues. Black arrowhead showed CXCL13 + CD8 + T cells (left panel). Immunohistochemistry (IHC) staining for CXCL13 (median panel), CD8 (right panel) and corresponding negative control were also shown. Neg ctrl refers to negative control. (b) Association between CXCL13 + CD8 + T cell signature and different ACRG classifications. Kruskal-Wallis test followed by Dunn's multiple comparisons test, * P < .05, ** P < .01, *** P < .001, ns refers to not significant. (c) Association between the number of CXCL13 + CD8 + T cells and patient survival outcomes. Mann-Whitney U test, * P < .05, ** P < .01, *** P < .001, ns refers to not significant. (d-e) Kaplan-Meier curves (d) for overall survival (OS) according to the number of intratumor CXCL13 + CD8 + T cells and multivariate analysis (e) based on clinicopathological characteristics in Testing set (n = 220) and Validation set (n = 220), respectively. The OS was compared between CXCL13 + CD8 + T high and CXCL13 + CD8 + T low subgroups. Log-rank test was performed for Kaplan-Meier curves. HR refers to hazard ratio, CI refers to confidence interval
